Omeprazole with Risedronate Interaction Details
Brand Names Associated with Omeprazole
- Omeprazole
- Prilosec®
- Prilosec® OTC
- Talicia (as a combination product containing Amoxicillin, Omeprazole, Rifabutin)
- Zegerid® (as a combination product containing Omeprazole, Sodium Bicarbonate)
- Zegerid® OTC (as a combination product containing Omeprazole, Sodium Bicarbonate)
Brand Names Associated with Risedronate
- Actonel®
- Actonel® with Calcium (as a combination product containing Calcium, Risedronate)
- Atelvia
- Risedronate
Medical Content Editor Dr. Brian Staiger, PharmD
Last updated
Nov 05, 2023
Interaction Effect
Increased risedronate bioavailability
Interaction Summary
Concomitant administration of enteric-coated risedronate sodium (Atelvia(TM)) delayed-release tablets and a proton pump inhibitor, such as omeprazole, may increase the bioavailability of risedronate. In drug interaction studies between risedronate delayed-release tablets and esomeprazole, also a proton pump inhibitor, the Cmax and AUC of risedronate increased 60% and 22%, respectively. Due the possible increase in risedronate bioavailability, the concomitant use of omeprazole and enteric-coated risedronate sodium (Atelvia(TM)) delayed-release tablets is not recommended .
Severity
Moderate
Onset
Unspecified
Evidence
Theoretical
How To Manage Interaction
Coadministration of enteric-coated risedronate sodium (Atelvia(TM)) delayed-release tablets and proton pump inhibitors, such as omeprazole, may result in increased risedronate bioavailability. Concomitant use is not recommended .
Mechanism Of Interaction
Increased stomach pH resulting in faster release of enteric-coated products
Literature Reports
A) During a phase 1, 2-period, crossover study of 60 healthy postmenopausal women coadministration of esomeprazole, a proton pump inhibitor like omeprazole, and delayed-release risedronate tablet resulted in increased risedronate AUC and Cmax. The women were administered a single dose of delayed-release risedronate 35 mg after breakfast following 6 days of treatment with delayed-release esomeprazole 40 mg. On day 6, esomeprazole 40 mg was administered one hour prior to breakfast with 240 mL of water. Risedronate delayed-release 35 mg was administered within 10 minutes of breakfast with an additional 240 mL of water. Laboratory tests revealed an increase of 60% and 22% in risedronate Cmax and AUC, respectively, in the presence of esomeprazole .
Omeprazole Overview
-
Prescription omeprazole is used alone or with other medications to treat the symptoms of gastroesophageal reflux disease (GERD), a condition in which backward flow of acid from the stomach causes heartburn and possible injury of the esophagus (the tube between the throat and stomach) in adults and children 1 year of age and older. Prescription omeprazole is used to treat damage from GERD in adults and children 1 month of age and older. Prescription omeprazole is used to allow the esophagus to heal and prevent further damage to the esophagus in adults and children 1 year of age and older with GERD. Prescription omeprazole is also used to treat conditions in which the stomach produces too much acid such as Zollinger-Ellison syndrome in adults. Prescription omeprazole is also used to treat ulcers (sores in the lining of the stomach or intestine) and it is also used with other medications to treat and prevent the return of ulcers caused by a certain type of bacteria (H. pylori) in adults. Nonprescription (over-the-counter) omeprazole is used to treat frequent heartburn (heartburn that occurs at least 2 or more days a week) in adults. Omeprazole is in a class of medications called proton-pump inhibitors. It works by decreasing the amount of acid made in the stomach.
Risedronate Overview
-
Risedronate tablets and delayed-release (long-acting tablets) are used to prevent and treat osteoporosis (a condition in which the bones become thin and weak and break easily) in women who have undergone menopause (''change of life,'' end of menstrual periods). Risedronate tablets are also used to treat osteoporosis in men, and in men and women who are taking glucocorticoids (a type of corticosteroid medication that may cause osteoporosis). Risedronate tablets are also used to treat Paget's disease of bone (a condition in which the bones are soft and weak and may be deformed, painful, or easily broken). Risedronate is in a class of medications called bisphosphonates. It works by preventing bone breakdown and increasing bone density (thickness).
Return To Our Drug Interaction Homepage
Feedback, Question Or Comment About This Information?
Ask Dr. Brian Staiger, PharmD, our medical editor, directly! He's always more than happy to assist.
Definitions
Severity Categories
Contraindicated
These drugs, generally, should not be used together simultaneously due to the high risk of severe adverse effects. Combining these medications can lead to dangerous health outcomes and should be strictly avoided unless otherwise instructed by your provider.
Major
This interaction could result in very serious and potentially life-threatening consequences. If you are taking this drug combination, it is very important to be under close medical supervision to minimize severe side effects and ensure your safety. It may be necessary to change a medication or dosage to prevent harm.
Moderate
This interaction has the potential to worsen your medical condition or alter the effectiveness of your treatment. It's important that you are monitored closely and you potentially may need to make adjustments in your treatment plan or drug dosage to maintain optimal health.
Minor
While this interaction is unlikely to cause significant problems, it could intensify side effects or reduce the effectiveness of one or both medications. Monitoring for changes in symptoms and your condition is recommended, and adjustments may be made if needed to manage any increased or more pronounced side effects.
Onset
Rapid: Onset of drug interaction typically occurs within 24 hours of co-administration.
Delayed: Onset of drug interaction typically occurs more than 24 hours after co-administration.
Evidence
Level of documentation of the interaction.
Established: The interaction is documented and substantiated in peer-reviewed medical literature.
Theoretical: This interaction is not fully supported by current medical evidence or well-documented sources, but it is based on known drug mechanisms, drug effects, and other relevant information.
How To Manage The Interaction
Provides a detailed discussion on how patients and clinicians can approach the identified drug interaction as well as offers guidance on what to expect and strategies to potentially mitigate the effects of the interaction. This may include recommendations on adjusting medication dosages, altering the timing of drug administration, or closely monitoring for specific symptoms.
It's important to note that all medical situations are unique, and management approaches should be tailored to individual circumstances. Patients should always consult their healthcare provider for personalized advice and guidance on managing drug interactions effectively.
Mechanism Of Interaction
The theorized or clinically determined reason (i.e., mechanism) why the drug-drug interaction occurs.
Disclaimer: The information provided on this page is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional regarding your specific circumstances and medical conditions.
Where Does Our Information Come From?
Information for our drug interactions is compiled from several drug compendia, including:
The prescribing information for each drug, as published on DailyMED, is also used.
Individual drug-drug interaction detail pages contain references specific to that interaction. You can click on the reference number within brackets '[]' to see what reference was utilized.
The information posted is fact-checked by HelloPharmacist clinicians and reviewed quarterly.